Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders

S Oertle; H Mauron; PN Villiger

doi:10.4414/smw.2002.10031

Original article

Vol. 132 No. 2930 (2002)

Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders

S Oertle
H Mauron
PN Villiger

Fulltext PDF

Cite this as:: Swiss Med Wkly. 2002;132:414-414
Published: 27.07.2002

How to Cite

1.

Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders. Swiss Med Wkly [Internet]. 2002 Jul. 27 [cited 2025 Nov. 5];132(2930):414-. Available from: https://smw.ch/index.php/smw/article/view/197

Share

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

DOI:: https://doi.org/10.4414/smw.2002.10031